In the Claims:

Please amend claims 3, 4, 14, 16, 17, 19, 20, 23, and 39 as indicated below. Please cancel claims 1, 2, 5-13, 18, 21-22, 24-25, 28-29, 31-38, and 41-59 without prejudice. This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Canceled)

2. (Canceled)

3. (Currently amended) An immunogenic composition, comprising: a first polypeptide, which is autologous to a subject or which is immunologically cross-reactive with the autologous polypeptide, coupled to a second polypeptide, which is heterologous to the subject, wherein the first polypeptide comprises an immunogenic portion of a polypeptide specifically expressed on the surface of activated B cells and wherein the second polypeptide contains at least one T helper cell epitope, the composition being capable of eliciting an immune response against ~~an autologous antigen~~ B cells in the subject.

4. (Currently amended) The composition of claim 3 or 17, wherein the first polypeptide is a human polypeptide and the subject is a human.

5-13. (Canceled)

14. (Currently amended) The composition of claim 3 or 17, wherein the first polypeptide and the second polypeptide are expressed as a fusion protein.

15. (Original) The composition of claim 14, wherein the fusion protein is dimeric.

16. (Currently amended) The composition of claim 3 or 17, wherein the first polypeptide and the second polypeptide are coupled via a chemical linkage.

17. (Currently amended) ~~The composition of claim 3,~~ An immunogenic composition, comprising: a first polypeptide which is autologous to a subject or which is immunologically cross-reactive with the autologous polypeptide coupled to a second polypeptide which is heterologous to the subject, wherein the first polypeptide comprises ~~at least a~~ an immunogenic portion of a molecule selected from the group consisting of: CD79α, CD79β, and CD20 ~~, and Ig~~ and wherein the second polypeptide comprises at least one T helper cell epitope, the composition being capable of eliciting an immune response against B cells in the subject.

18. (Canceled)

19. (Currently amended) The composition of claim 3 or 17, wherein the second polypeptide comprises at least a portion of an Fc region of an immunoglobulin molecule.

20. (Currently amended) ~~A~~ An immunogenic composition comprising a first polypeptide which is autologous to a subject or which is immunologically cross-reactive with the autologous polypeptide to the ~~a human~~ subject coupled to a second polypeptide which is heterologous to the ~~human~~ subject, wherein the first polypeptide comprises an immunogenic portion of a polypeptide specifically expressed on the surface of cells targeted for elimination or reduction and the second polypeptide comprises at least one T helper cell epitope, and wherein the composition is capable of ~~eliciting an immune response to an autologous antigen targeted for reduction or elimination~~ reducing or eliminating the population of cells expressing the cell surface receptor.

21. (Canceled)

22. (Canceled)

23. (Currently amended) The composition of claim 20, wherein the autologous antigen is selected from the group consisting of: CD64, ~~sL-selectin,~~ elastase, ~~sCD16,~~ CD46, ~~TNF-α,~~ ~~sTNF-R75, sTNF-R55, TGF-β,~~ CD40, CD154, ~~lipoprotein (a),~~ CD56, ~~IL-10, IFN-γ, IL-2, IL-2R,~~ CD45, ~~IL-4, IgE,~~ EGFR, ~~TGF-β,~~ CD54, ~~sCD44-v5,~~ and CD95.

24. (Canceled)

25. (Canceled)

26. (Original) The composition of claim 20, wherein the first polypeptide and the second polypeptide are expressed as a fusion protein.

27. (Original) The composition of claim 26, wherein the fusion protein is dimeric.

28. (Canceled)

29. (Canceled)

30. (Original) The composition of claim 20, wherein the second polypeptide comprises at least a portion of an Fc region of an immunoglobulin molecule.

31-38. (Canceled)

39. (Currently Amended) ~~A~~ An immunogenic composition comprising a first polypeptide which is autologous to a subject or which is immunologically cross-reactive with the autologous ~~human~~ polypeptide coupled to a second polypeptide ~~comprising at least a portion of a non-human immunoglobulin molecule~~ which is heterologous to the subject, wherein the first polypeptide comprises an immunogenic portion of a cell surface polypeptide specifically expressed on the surface of B cells and the second polypeptide comprises at least one T helper cell epitope, the composition being capable of eliciting an immune response against B cells in the subject.

40. (Original) The composition of claim 39, wherein the portion of the non-human immunoglobulin molecule is derived from the Fc portion of the immunoglobulin.

41- 59. (Canceled)

60. (New) The composition of any one of claims 3, 17, 20, or 39, wherein the first polypeptide

comprises the extracellular domain of a cell surface polypeptide.

61. (New) The composition of claim 3, 17, or 39, wherein the number or concentration of cells expressing the polypeptide in the subject is reduced by at least about 35-40% relative to the number or concentration of cells prior to treatment or in an untreated subject.

62. (New) The composition of claim 3, 17, or 39, wherein the number or concentration of cells expressing the polypeptide in the subject is reduced by at least about 50% relative to the number or concentration of cells prior to treatment or in an untreated subject.

63. (New) The composition of claim 20, wherein the molecule is selected from the group consisting of: TNFR, IL-4R, IL-12R, IL-2R, EGFR, PDGFR, and bombesin receptor.

64. (New) The composition of claim 20, wherein the molecule is selected from the group consisting of: CTLA4, CD3, membrane Ig, TCR, and FCR

65. (New) The composition of claim 20, wherein the molecule is selected from the group consisting of: CD81, CD21, CD19, CD79, CD32, CD80, CD86, CD40, CD11a/CD18, CC22, CD45, CD28, CD2, CD4, CD8, CD154, CD54, CD43, and CD45.RO.

66. (New) The composition of claim 20, wherein the molecule is selected from the group consisting of: CD64, CD46, CD56, and CD95.

67. (New) The composition of claim 20, wherein the molecule is selected from the group consisting of: CD79α, CD79β, CD20, and CD19.

68. (New) The composition of any one of claims 3, 17, 20, or 39, wherein the composition further comprises an adjuvant.